Zusammenfassung
Die Osteoporose ist eine klassische altersassoziierte Erkrankung, welche Frauen häufiger als Männer betrifft. Die Hypothese, daß die Osteoporose infolge einer Östrogendefizienz auftritt, wurde bereits 1941 von Albright et al. [1] aufgestellt. Die molekularbiologischen Wirkungsmechnismen der Östrogendefizienz postmenopausaler Frauen sowie älterer Männer werden in einer Vielzahl laufender Studien untersucht. Die Östrogendefizienz hat sowohl direkte als auch indirekte Einflüsse auf den Knochenmetabolismus, welche allesamt zu einer intensivierten Osteoklastogenese führen. Diese Übersichtsarbeit beleuchtet sowohl die endokrinologischen als auch die osteoimmunologischen Mechanismen, die zur Involutionsosteoporose führen.
Summary
Osteoporosis is a classical age-related disease that affects women more often than men. The hypothesis that osteoporosis is a consequence of estrogen deficiency, has been proposed as early as 1941 by Albright and colleagues [1]. The exact mechanisms of this steroid hormone deficiency in postmenopausal women as well as in the elderly men are continuously being unraveled. Collectively, estrogen deficiency has direct as well as indirect impacts on bone metabolism all of which promote osteoclastogenesis. This review aims at shedding light on the endocrine and osteoimmunological mechanisms that lead to involutional osteoporosis.
References
Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. J Am Med Assoc, 116: 2465–2474, 1941
Anonymous. Osteoporosis prevention, diagnosis and therapy. J Am Med Assoc, 285: 785–795, 2001
Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. Perspective. The diagnosis of osteoporosis. J Bone Miner Res, 9: 1137–1141, 1994
Riggs BL, Melton LJ III. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med, 75: 899–901, 1983
Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis:estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res, 13: 763–773, 1998
Duque G, Troen BR. Understanding the mechanisms of senile osteoporosis: new facts for a major Geriatric syndrome. J Am Geriatr Soc, 56: 935–941, 2008
Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol, 143: 31–48, 2007
Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signalling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem, 15: 127–136, 2008
Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL. Evidence of estrogen receptors in normal human osteoblast-like cells. Science, 241: 84–86, 1988
Komm BS, Terpening CM, Benz DJ, Graeme KA, O'Malley BW, Haussler MR. Estrogen binding receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science, 241: 81–84, 1988
Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA, 88: 6613–6617, 1998
Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology, 142: 2205–2212, 2001
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest, 111: 1120–1122, 2003
Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone, 32: 136–141, 2003
Heaney RP, Recker RR, Saville PD. Menopause changes in calcium balance performance. J Lab Clin Med, 92: 953–963, 1978
McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, Riggs BL. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause – a clinical research center study. J Clin Endocrinol Metab, 80: 3458–3464, 1995
Gennari C, Agnusdei D, Nardi P, Civitelli R. Estrogen preserves a normal intestinal responsiveness to 1,25-dihydroxyvitamin D3 in oophorectomized women. J Clin Endocrinol Metab, 71: 1288–1293, 1990
Cosman F, Nieves J, Horton J, Shen V, Lindsay R. Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women. J Clin Endocrinol Metab, 78: 939–943, 1994
Cosman F, Shen V, **e F, Seibel M, Ratcliffe A, Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Ann Intern Med, 118: 337–343, 1993
Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest, 64: 729–736, 1979
Tsai K-S, Heath H III, Kumar R, Riggs BL. Impaired vitamin D metabolism with aging in women: possible role in pathogenesis of senile osteoporosis. J Clin Invest, 73: 1668–1672, 1984
Ebeling PR, Snadgren ME, DiMagno EP, Lane AW, DeLuca HF, Riggs BL. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: Relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J Clin Endocrinol Metab, 75: 176–182, 1992
Pacifici R, Rifas L, McCracken R, Vered I, McMurtry C, Avioli LV, Peck WA. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci USA, 86: 2398–2402, 1989
Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology, 125: 825–833, 1989
Oursler MJ, Cortese C, Keeting PE, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC. Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology, 129: 3313–3320, 1991
Pacifici R. T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther, 9: 102, 2007
Robbie-Ryan M, Pacifici R, Weitzmann MN. IL-7 drives T cell-mediated bone loss following ovariectomy. Ann N Y Acad Sci, 1068: 348–351, 2006
Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R. IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest, 117: 122–132, 2007
Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger E, Peterlik M. Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractues. Exp Gerontol, 36: 1749–1759, 2001
Zheng SX, Vrindts Y, Lopez M, De Groote D, Zngerle PF, Collette J, Franchimont N, Geenen V, Albert A, Reginster JY. Increase in cytokine production (IL-1β, IL-6, TNF-α but not IFN-γ, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas, 26: 63–71, 1997
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci, 908: 244–254, 2000
Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willheim M, Woloszczuk W, Peterlik M, Tragl KH. The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol, 38: 1119–1127, 2003
Weitzamnn MN, Pacifici R. T cells: unexpected plyaers in the bone loss induced by estrogen deficieny and in basal bone homeostasis. Ann N Y Acad Sci, 1116:360–375, 2007
Grassi F, Tell G, Robbie-Ryan M, Gao Y, Terauchi M, Yang X, Romanello M, Jones DP Weitzmann MN, Pacifici R. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci USA, 104: 15087–15092, 2007
Cenci S, Toraldo G, Weitzmann MN, Roggin C, Gao Y, Qian WP, Sierra O, Pacifici R. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator. Proc Natl Acad Sci USA, 100: 10405–10410, 2003
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell, 89: 747–754, 1997
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89: 755–764, 1997
Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem, 276: 37731–37734, 2001
Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology, 143: 2376–2384, 2002
Kim SW, Her SJ, Kim SY, Shin CS. Ectopic overexpression of adipogenic transcription factors induces transdifferentiation of MC3T3-E1 osteoblasts. Biochem Biophys Res Commun, 327: 811–819, 2005
Taleb S, Lacasa D, Bastard JP, Poitou C, Cancello R, Pelloux V, Viguerie N, Benis A, Zucker JD, Bouillot JL, Coussieu C, Basdevant A, Langin D, Clement K, Cathepsin S. A novel biomarker of adiposity: relevance to atherogenesis. FASEB J, 19: 1540–1542, 2005
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sipos, W., Pietschmann, P., Rauner, M. et al. Pathophysiology of osteoporosis. Wien Med Wochenschr 159, 230–234 (2009). https://doi.org/10.1007/s10354-009-0647-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-009-0647-y